R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Phase 2 Completed 40 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of R115777 in treating patients who have metastatic pancreatic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Timeline

Start: 2000-05
Primary completion: 2004-09
Completion: —

Outcome

Missed primary endpoint

paper No objective responses were seen. PMID 12663718 ↗

paper it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer. PMID 12663718 ↗

Publications

Results Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003 Apr 1;21(7):1301-6. doi: 10.1200/JCO.2003.08.040.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	300 mg	Oral